M. Zheng

发表

Physiologically‐based pharmacokinetic modelling of a CYP2C19 substrate, BMS‐823778, utilizing pharmacogenetic data

L. Iacono, R. Iyer, J. Gong, 2018, British journal of clinical pharmacology.

S-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling

Wei Li, G. Tipoe, Yingxia Liu, 2020, Acta pharmaceutica Sinica. B.

Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study

Z. Bhagwagar, R. Risinger, W. Hayes, 2014, Psychopharmacology.

Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836

Z. Bhagwagar, R. Risinger, G. Antoni, 2015, Psychopharmacology.

Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model

Andy Z. X. Zhu, Yuan Chen, E. Schuck, 2019, CPT: pharmacometrics & systems pharmacology.

Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective

Andy Z. X. Zhu, Yuan Chen, I. Poggesi, 2020, Clinical pharmacology and therapeutics.

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

Malcolm Rowland, Shinji Yamazaki, Jun Chen, 2018, Clinical pharmacology and therapeutics.

Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

N Parrott, H M Jones, Y Chen, 2015, Clinical pharmacology and therapeutics.

PBPK models for evaluating membrane transporter mediated DDIs: Current capabilities, case studies, future opportunities and recommendations.

Yuichi Sugiyama, Ming Zheng, Jan Snoeys, 2019, Clinical pharmacology and therapeutics.

Projection of Exposure and Efficacious Dose Prior to First-in-Human Studies: How Successful Have We Been?

A. D. Rodrigues, P. Marathe, Christine S. Huang, 2008, Pharmaceutical Research.

Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies

R. Shelton, M. Thase, Z. Bhagwagar, 2015, Journal of clinical psychopharmacology.

Pharmacokinetic-Pharmacodynamic Modeling of Rifampicin-Mediated Cyp3a11 Induction in Steroid and Xenobiotic X Receptor Humanized Mice

J. Raybon, D. G. Morgan, M. Zheng, 2011, Journal of Pharmacology and Experimental Therapeutics.

Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study

Z. Bhagwagar, R. Risinger, W. Hayes, 2013, Psychopharmacology.

Safety, pharmacokinetic, and positron emission tomography evaluation of serotonin and dopamine transporter occupancy following multiple-dose administration of the triple monoamine reuptake inhibitor BMS-820836

Z. Bhagwagar, R. Risinger, G. Antoni, 2014, Psychopharmacology.